Salute e Benessere

Independent European data on CP-GEP model in Stratifying Melanoma Patients for…

While a nodal assessment by means of the SLNB surgery remains the gold standard for clinical staging of cutaneous melanoma, not all eligible patients might undergo this invasive procedure. Node biopsies in the head and neck location may be challenging due to the regional course of nerves and lymphatic drainage2. The second study, led by Dr. Amaral from University of Tuebingen, Germany, assessed the performance of the CP-GEP model in a group of patients that did not undergo the SLNB procedure…

Postponement Annual Shareholders Meeting - Amendment financial calendar

Postponement Annual Shareholders Meeting - Amendment financial calendarLeuven, BELGIUM – April 5, 2024 – 02:00 PM CETOxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today made the following announcement regarding its financial calendar. Due to administrative reasons, the annual accounts of the Company have not been finalized yet. Hence, the Company has decided to postpone its Annual Shareholders Meeting to Thursday May 16, 2024.The...

In coordination with DoH J.P. Morgan's Life Sciences Private Capital announces…

Finalists selected to compete in the summit include: Finalists selected to compete in the summit include: Stephen Squinto, PhD, Chief Investment Officer, J.P. Morgan Life Sciences Private Capital said: "We are very pleased to be partnering with the stellar leadership of the Department of Health –Abu Dhabi, Blue Horizon Advisors, United AlSaqer Group, Cleveland Clinic Abu Dhabi and other local leaders in launching our inaugural innovation summit." Nabil Kobeissi, Chief Executive...

OMRON Healthcare Acquires Luscii Healthtech to Advance and Innovate Remote…

Logo: https://kyodonewsprwire.jp/img/202404028932-O1-b1ehIMr2 Logo:https://kyodonewsprwire.jp/img/202404028932-O1-b1ehIMr2 Luscii provides a fully customizable platform and app for care at home, catering to over 150 diseases, including those affecting chronic hypertensive, cardiovascular, and respiratory patients. As the market leader inthe Netherlands, where Luscii collaborates with approximately 70% of the country's hospitals, the platform also extends its presence to other...

Photocure to Participate in the 23rd Annual Needham Virtual Healthcare…

Date: April 11, 2024 Date: April 11, 2024 Time:10:15am ET ( 4:15pm CET ) Webcast Link: https://wsw.com/webcast/needham117/pho.ol/2531984 About the Needham Healthcare Conference The 23 rdAnnual Needham Virtual Healthcare Conference will feature leading public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology, and Diagnostics sectors. About Photocure ASA Photocure: The Bladder Cancer Company delivers transformative...

SkinPen® Precision Now Available through DUBIMED in the Gulf States

Access to SkinPen will significantly benefit these Gulf States countries' healthcare professionals and their customers. Accounts will be able to offer their patients the #1 and best-in-class* US microneedling device available today, backed by an elite level of Customer Service and Training that SkinPen Precision customers and patients have come to expect across the globe. Access to SkinPen will significantly benefit these Gulf States countries' healthcare professionals and their customers...

CORRECTION -- NeuroVigil, World's Most Valuable Neurotech Company, Launches in…

CLOSED 6 BILLION DOLLAR SERIES B DEAL Silicon Valley-based Neurotechnology Powerhouse, announced that it launched its non-invasive iBrain™ Personal Brain Monitor, in 4 US states on Friday and sold 1.4% of its stock for more than $85 million on Saturday, valuing the company at over $6 Billion in the highest Series B financing in History by a margin of $4.5 Billion, at over 12 times Facebook's Series B valuation. The invitation-only financing itself, with 27 Strategic Investors, including a...

NeuroVigil, World's Most Valuable Neurotech Company, Launches in US

CLOSED 6 BILLION DOLLAR SERIES B DEAL In the first phase of the launch, iBrain, positioned as an investigational device, will hunt for biomarkers of apnea, aneurysms and drug side effects in asymptomatic individuals, as it has in partnership with Roche and Novartis, NeuroVigil's first paying clients since well over a decade. The investigators will initially not be allowed to modify anyone's therapy based on iBrain data. That can only happen following FDA-approved tests. In the second...

Gene Therapies in Ophthalmology Market to Register Immense Growth at a CAGR of…

Key Takeaways from the Gene Therapies in Ophthalmology Market Report Key Takeaways from the Gene Therapies in Ophthalmology Market Report Discover which therapies are expected to grab the major gene therapy in ophthalmology market share @Gene Therapy in Ophthalmology Market Report Gene Therapy in Ophthalmology Overview Gene therapy is becoming a promising solution for retinal degenerative illnesses, particularly due to the retina's suitability for studying and treating eye conditions...

Information regarding the total number of voting rights and total number of…

Information regarding the total number of voting rights andtotal number of shares of the Company as of March 31, 2024 (Article 223-16 of the General Regulations of theAutorité des...

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext Growth ISIN code: FR0010425595DateTotal number of shares in the capitalTotal number of voting rights 03/31/202471,953,53577,889,229 For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the...

GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

Cash and cash equivalents totaled €77.8 million as of December 31, 2023Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 millionTopline interim data for Phase 2 UNVEIL-IT ®trial in ACLF expected in 2H24FDA PDUFA action date for elafibranor in PBC: June 10, 2024 Lille, France; Cambridge, MA; Zurich, Switzerland; April 4, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to...

Galapagos showcases innovative approach in hematological cancer care with…

Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / Richter transformation (RT)Mechelen, Belgium; 4 April 2024, 22:01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that four abstracts, including two oral presentations on encore preliminary clinical and translational data for its seven-day vein-to-vein CAR-T product candidates GLPG5101 and GLPG5201,...

Declaration of voting rights - Valneva SE, March 2024

VALNEVADeclaration of shares and voting rightsMarch 31, 2024__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: April 4, 2024 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights* Description of the change...

Appointment of Stephen M. Deitsch as new Chief Financial Officer

OrganOx, a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer (“CFO”) on April 8, 2024. Steve joins OrganOx fromParagon 28(NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopaedic market, where he has held the role of CFO since...

LBB Specialties Announces Principal Partnership with VIZOR

VIZOR's newly expanded R&D lab in Brooklyn, NY and its state-of-the-art manufacturing facility in Middlesex County, NJ, are poised to meet customer demand for innovation and product launches. Leveraging proprietary technologies, VIZOR® specializes in the development and industrial-scale production of mineral-based sunscreen actives, ensuring unparalleled efficacy while focusing on sustainability. VIZOR'snewly expanded R&D lab inBrooklyn, NYand its state-of-the-art manufacturing...

IRBM to Disclose Strong Antitumor Efficacy of Novel Preclinical Agents Against…

Carlo Toniatti, MD, PhD, Chief Scientific Officer at IRBM, expressed his enthusiasm for the upcoming presentations: "The AACR meeting presents a unique opportunity for IRBM to share our latest advancements in cancer research with the global scientific community. Our work on the CRLF2/TLSPR targeting ADC and CNS-penetrant SHP2 small molecule inhibitor exemplifies our relentless pursuit of novel therapeutic strategies that can make a significant difference in the lives of patients battling…

Rising Cancer Burden and Acceptance of Novel Treatments Drive Global Cell…

Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-19414 Download the Sample PDF report to explore key market insights and trends:https://www.futuremarketinsights.com/reports/sample/rep-gb-19414 Several factors are fueling the growth of the cell therapy growth factor industry. One such factor is the growing attractiveness of cell therapy as a treatment method for a wide variety of illnesses and ailments...

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating…

Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patients and early signs of anti-tumor activity Enrollment in Part 2 dose expansion has been initiated LAUSANNE, Switzerland, April04, 2024(GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial...

myTomorrows and brainstrust Partner to Support the Brain Cancer Community in…

There are 80,000 people living with a brain tumor in England alone, with a patient receiving a diagnosis every two hours. Brain tumors kill more children and adults under the age of 40 than any other cancer, and incidences and deaths from brain tumors are on the rise. There are 80,000 people living with a brain tumor inEnglandalone, with a patient receiving a diagnosisevery two hours. Brain tumors kill more children and adults under the age of 40 than any other cancer, and incidences and...

Carl Zeiss Meditec AG Completes Acquisition of Dutch Ophthalmic Research Center…

"Together we are better. Today holds significant importance for us as we bring our teams together and turn our collective attention toward delivering breakthrough innovations and solutions for our customers. We are very excited to welcome D.O.R.C.'s team members to our ZEISS family and to begin integrating our products and practices as we work toward a brighter future together," says Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG. "Together we are better . Today…

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q1 2024

The group revenue increased with 14 % for Q1 2024 compared with the first quarter last year and amounted to SEK 450.4 (393.7) million. The group revenue increased with 14 % for Q1 2024 compared with the first quarter last year and amounted toSEK 450.4(393.7) million. Revenues were distributed as follows: Countries in regions:-The Nordics:Denmark, Faroe Island,Finland,Iceland,Norway,Sweden- Central Europe :Austria,Germany,Switzerland- East Europe :...

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT…

Grifols' in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infectionsArboviruses are a growing emerging threat, with changes in climate and increasing global connectivity making the geographic spread more prevalentCE mark for Grifols' Procleix ArboPlex Assay reinforces the company's leadership in transfusion medicine and commitment to ensuring the safety of the world's blood supply BARCELONA, Spain, April...

Ariceum Therapeutics to present new radioligand therapy data at American…

Manfred Rüdiger, Chief Executive Officer at Ariceum Therapeutics, said: "Following our exclusive, strategic research collaboration with UCB, we look forward to presenting new findings related to the identification of highly specific macrocyclic peptides for use in radioligand therapeutics at this year's AACR Annual Meeting. These data have positive implications for the future development of RLT and are a potential game-changer in precision cancer therapy. AACR's Annual Meeting is the…

Altri Comunicati